Meeting
2019 Genitourinary Cancers Symposium
The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.
Presenter
Peter Albers, MD
Heinrich-Heine-University
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Oral Abstract Session B: Urothelial Carcinoma and Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Testicular Cancer
Clinical Trial Registration Number
NCT 2015053664
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 507)
DOI
10.1200/JCO.2019.37.7_suppl.507
Abstract #
507
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
The PRIMETEST trial: Prospective phase II trial of primary retroperitoneal lymph node dissection (RPLND) in stage II A/B patients with seminoma.
Speaker: Peter Albers, MD
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC): Interim analysis of ANTICIPATE phase II trial.
Speaker: Matt D. Galsky, MD, FASCO
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.
Speaker: Van K. Morris, MD
Speaker: Panel Discussion